<DOC>
	<DOC>NCT01218061</DOC>
	<brief_summary>The main objective of the study is to follow prospectively a cohort of patients with pre-diabetes to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population.</brief_summary>
	<brief_title>Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Adult patients (≥18 years) Subjects with diabetes risk score ≥ 15 Subjects with impaired fasting glucose: blood glucose ≥ 1.10 g/l and &lt; 1 .26 g/L Subjects affiliated with an appropriate social security system Fasting glycemia ≥ 1.26 g/l Fasting glycemia ≤ 1.10 g/l Subjects previously treated with oral antidiabetic: metformin, glitazones, inhibitors of αglucosidase, sulfonylurea, repaglinide, inhibitors of DPPIV, GLP1 R agonists. Subjects previously treated with insulin, except gestational diabetes Severe coagulation disorders Thrombocytopenia &lt; 100 000/mm 3 Severe psychiatric disorders Severe renal insufficiency (creatinine clearance &lt; 30 ml/min) Severe hepatic insufficiency (TP &lt; 50%) Alcohol abuse (&gt; 30g/j) Patient's opposition Subject unable to follow the study during the 5 years of followup Subject exclusion period in a previous study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pre-diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Cohort</keyword>
	<keyword>Diabetes Risk Score</keyword>
</DOC>